Business Wire

MA-PRECISELY

14.12.2022 15:02:06 CET | Business Wire | Press release

Share
Precisely Expands Global Data Enrichment and Geo Addressing Coverage, Unlocking Location-Based Context for Customers Around the World

Precisely, the global leader in data integrity, today announced the regional expansion of its unique location identifier, the PreciselyID, for its World Points of Interest (POI) data offering. Points of interest located in the US, Canada, Belgium, Luxembourg, the Netherlands, United Kingdom, Ireland, France, Sweden, and Singapore now benefit from accurate, standardized, and meaningful data – allowing businesses to streamline location-based decision-making across multiple regions of operation.

Disruption from the pandemic and other world events has had a lasting impact on many aspects of day-to-day life, including shopping habits, work location, and travel behaviors – making it even more important for businesses to be able to access accurate and current data on points of interest.

But keeping POI data fresh is no small feat, even for companies such as Google, who recently revealed that it removed seven million fake business profiles and prevented 12 million from being created throughout 2021 alone. Standardizing POI data is just as difficult; differences in address standards, language, character variations, or a lack of accurate address data, make it challenging for companies to effectively operationalize data from multiple regions.

Unlike other address identifiers on the market that associate a business name to an address, the PreciselyID is appended to both the location’s coordinates and the address and will remain constant over time. If a business closes and a new one opens in the same location, Precisely processes this change so that the PreciselyID will reflect the attributes for the new point of interest. As a result, businesses that use addresses as a primary data input will always have access to the most accurate data about any given location, enabling insights without needing geospatial tools or specialized skillsets.

“Businesses today need reliable answers about the world around them. If a clothing boutique closes, and the location becomes a coffee shop, it has an impact on the level of traffic, and types of shoppers, workers, and visitors to that area,” said Dan Adams, SVP – Data and Operations, at Precisely. “That’s why we associate the PreciselyID with an address and location, so our customers always have access to accurate, verified, and standardized data for detailed insights that matter to their business.”

POIs enabled with the PreciselyID have been cleansed, standardized, and verified by Precisely’s best-in-class geo addressing. As a result, organizations can quickly enrich records with accurate data while saving processing time and simplifying complex geospatial analysis. With access to a portfolio of over 400 datasets containing more than 9,000 attributes, Precisely customers can increase the accuracy, usability, and overall value of their business data and build context for faster, more confident decisions.

The regional expansion unlocks new capabilities for a wide variety of industries, including:

  • Retail – Leveraging location insights for site selection and management, locating competition and demand to identify opportunities for new stores or consolidation
  • Financial Services - Validating merchant data and achieving a 360-degree view of the changing landscape they operate in
  • Insurance – Helping to understand adjacent risk – including whether a property is located near to a high-risk building, such as a chemical plant
  • Telecommunications – Obtaining a full view into the places where people congregate, supporting telcos with their goal of providing high levels of coverage and keeping customers connected
  • Public Sector – Understanding where people work, shop, and spend their leisure time, enhancing planning for public transport networks, emergency services, and planning

Precisely expects further expansion, with support for more countries added in the future. Learn more about how to seamlessly connect addresses, properties, and POI data with the PreciselyID here.

About Precisely

Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005542/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye